Search results
Showing 331 to 345 of 381 results for depression
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Pelvic floor dysfunction: prevention and non-surgical management (NG210)
This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.